VERACYTE LABS SD CORP

Veracyte Labs SD Corporation specializes in genomic diagnostic testing services for military and veteran healthcare systems, with a primary focus on prostate cancer risk stratification using the Decipher Genomic Classifier. The company delivers advanced molecular diagnostics that analyze tumor gene expression patterns to guide clinical decision-making, enabling precision oncology workflows for high-risk prostate cancer patients. Their technical expertise lies in next-generation sequencing data interpretation, bioinformatic pipeline validation, and laboratory-developed test (LDT) deployment within federal clinical environments. A key differentiator is their ability to integrate genomic insights into existing military and VA care pathways, supporting risk-adapted treatment planning and reducing overtreatment through evidence-based genomic profiling. The contractor maintains a sustained relationship with the Department of Veterans Affairs, providing ongoing genomic testing services for prostate cancer management, including cost-per-test evaluations and test protocol modifications. The Department of Defense is also a consistent client, commissioning Decipher testing for active-duty military personnel at medical centers such as MAMC, indicating alignment with DoD’s precision medicine initiatives for service members. These engagements reflect a pattern of long-term, repeat procurement focused on clinical utility and operational readiness. Veracyte Labs SD Corporation operates exclusively under NAICS 621511, classifying it as a medical laboratory specializing in diagnostic molecular pathology. Its market positioning centers on clinical genomics for urologic oncology, serving as a trusted provider of FDA-cleared and CLIA-certified genomic assays within government healthcare networks. The company’s focus is narrowly specialized, with no evidence of broader diagnostic or laboratory service diversification. As a 2L entity based in San Diego, California, Veracyte Labs SD Corporation is a small business with no disclosed federal certifications. Its geographic presence is centralized in Southern California, supporting its role as a specialized provider to federal health systems without broad regional or multi-state operational footprint.